|

XER-001 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Xerient Pharma1

Indications

  • Locally Advanced Pancreas Cancer1
  • Locally Advanced Pancreatic Ductal Adenocarcinoma1
  • Locally Advanced Pancreatic Adenocarcinoma1
  • Cancer1

Santa Fe, New Mexico1 trial

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Christus St. Vincent Regional Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.